Loading...
•
Sep 30, 2020
Surmodics Q4 2020 Earnings Report
Revenue decreased by 27% year-over-year and GAAP EPS resulted in ($0.22).
Key Takeaways
Surmodics reported a decrease in revenue for the fourth quarter of fiscal year 2020, with a GAAP loss per share. The company received FDA clearance for its PounceTM Thrombus Retrieval System.
Revenue of $22.5 million, a decrease of 27% year-over-year
GAAP EPS of ($0.22), non-GAAP EPS of ($0.18)
FDA clearance received for PounceTM Thrombus Retrieval System for non-surgical removal of clots from the peripheral arterial vasculature
Cash from operating activities totaled $1.3 million
Surmodics
Surmodics
Surmodics Revenue by Segment
Revenue by Segment
Medical Device Revenue
CapyFin.comIn Vitro Diagnostics Revenue
CapyFin.com Forward Guidance
Due to the continued uncertainty surrounding the duration and magnitude of the COVID-19 pandemic, the Company will not provide financial guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income